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Introduction
Human immunodeficiency virus (HIV) is associated with neurological complications, including 
neurocognitive impairment. The early screening neuropsychological tests were designed to assess 
cortical functions.1,2
The widely used screening tests, such as the International HIV Dementia Scale (IHDS), mainly 
assess cortical function and are not sensitive to the milder forms of neurocognitive impairment. 
HIV-associated neurocognitive disorder (HAND) has, however, been shown to mainly affect 
subcortical functions.3
Adherence is one of the major determinants of successful viral suppression among people living 
with HIV (PLWHIV) on antiretroviral therapy (ART).4 Mbugua found out that in the HIV-positive 
patients attending the HIV clinic, 52% of the patients had an adherence rate of 95% or more, while 
48% had suboptimal adherence, which was defined as an adherence less than 95%.4 Advisory 
documents indicate that an adherence rate of 95% is necessary for successful viral suppression.5,6 
There are many causes of poor adherence, some of which are attributed to neurocognitive 
impairment that may be asymptomatic or mild, and thus go clinically unrecognised if not assessed.3
The American Academy of Neurology (AAN) has identified two forms of HAND since 1991, 
namely minor cognitive motor disorder (MCMD) and HIV-associated dementia (HAD).
Background: Asymptomatic cognitive impairment in human immunodeficiency virus (HIV)-
infected patients has recently been recognised as part of HIV-associated neurocognitive 
disorders. This has been implicated as one of the causes of poor adherence to antiretroviral 
therapy (ART).
Objective: To assess the association between neurocognitive impairment (asymptomatic and 
mild forms) and adherence to ART.
Methods: This was a cross-sectional survey involving 218 participants consecutively sampled 
from those attending the HIV treatment clinic at Aga Khan University Hospital in Nairobi. 
Data collected included quantitative primary data on pre-defined baseline characteristics, 
neurocognitive assessment by Montreal Cognitive Assessment (MoCA) tool (Appendix 1), 
instrumental activities of daily living by Lawton score and objective and subjective adherence 
measures by medication possession ratio (MPR) and simplified medication adherence 
questionnaire (SMAQ) (see Appendix 2). Univariate and bivariate analyses were conducted to 
determine the strengths of association between predictor and the outcome variables.
Results: Among the 218 participants in the study, a total of 69% had asymptomatic to mild 
neurocognitive impairment as assessed by the MoCA tool, while a total of 66% were determined 
as being adherent to ART by objective measures (by MPR) compared to subjective rates of 
77% as assessed by SMAQ. However, no statistically significant association was observed 
between the presence of asymptomatic or mild neurocognitive impairment and likelihood of 
adherence to ART (p > 0.05).
Conclusion: Even though asymptomatic and mild forms of cognitive impairment are prevalent 
in the population studied, there was no significant association between cognitive impairment 
and adherence to treatment.
The association between asymptomatic and mild 
neurocognitive impairment and adherence to 
antiretroviral therapy among people living with human 
immunodeficiency virus
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The HIV Neurobehavioral Research Centre (HNRC) modified 
the criteria, to include an additional group, and these criteria 
were adopted by the AAN in 2007.7 The modified criteria, 
also known as the Frascati criteria, recognised the following 
three conditions: asymptomatic neurocognitive impairment 
(ANI), HIV-associated mild neurocognitive disorder (MND) 
and HAD. The notable addition was ANI, as research has 
shown a considerable number of HIV patients with clinically 
demonstrable cognitive abnormality but no impairment of 
function.7 Asymptomatic neurocognitive impairment refers 
to the patients with acquired cognitive impairment in at least 
two ability domains, but the impairment does not interfere 
with everyday functioning. MND refers to acquired cognitive 
impairment involving at least two ability domains, with mild 
interference in daily functioning either by self-report or 
observation by others. HIV-associated dementia refers 
to marked acquired cognitive impairment with marked 
interference in day-to-day functioning.7 ANI and MND are 
the mild forms of HAND.
Literature review
Human immunodeficiency virus is a neurotropic infection 
and invades the central nervous system from the time of 
primary infection.8
The introduction of ART heralded a significant change in the 
spectrum of HAND, with prevalence of HAD decreasing and 
the prevalence of the milder forms of HAND increasing, 
predominantly ANI. Therefore, relying on self-report, as was 
the case previously, missed out this population.7
In a study carried out in Botswana among HIV-positive 
patients attending HIV clinic to assess the neurocognitive 
impairment, it was found that despite 97.5% of the patients 
being on ART, 38% of the population had neurocognitive 
impairment as assessed by the IHDS. According to this 
study, more than one-third of the population studied had 
neurocognitive impairment despite being on ART for more 
than two years, and one of the reasons for this finding was 
attributed to the likely poor adherence to ART.9
Another study carried out at Kenyatta National Hospital 
(KNH) in 2011 utilised IHDS to assess cognitive function and 
determined the prevalence of neurocognitive impairment in 
HIV-positive patients to be 26%, of which 23% were not 
on ART.10
A meta-analysis of studies on prevalence of HAND in HIV-
positive patients on ART for more than six months (data 
collected up to June 2012, and using the IHDS) in seven 
countries in sub-Saharan Africa (Uganda, Zambia, Malawi, 
Botswana, Nigeria, Cameroon and South Africa) concluded 
that the prevalence of neurocognitive impairment was more 
than 30%.11
The CNS HIV Antiretroviral Therapy Effects Research 
(CHARTER) Study is a landmark longitudinal prospective 
study that was carried out in the ART era and as illustrated 
below, the most prevalent form of HAND was found to be 
the ANI followed by MND.12
The IHDS has been shown to be effective in screening for 
HAD; however, it is not accurate for screening for mild 
cognitive impairment as it either over-reports or under-
reports impairment. The IHDS assesses only cortical function 
and thus can miss out patients with subcortical dysfunction, 
as in HAND. Over-reporting can be caused by human error 
among people administering the IHDS. 13,14,15,16
The Montreal Cognitive Assessment (MoCA) tool used for 
assessing subcortical function has shown promise in HIV 
mild cognitive impairment.15,17 It is a 10-min test that is ideal 
as a screening test.
The MoCA has been validated and widely used in many 
countries, in non-HIV populations, to screen for milder 
forms of cognitive impairment. With a cut-off less than 26 for 
mild neurocognitive impairment, the sensitivity was 83% 
and the specificity was 81%.18 However, in PLWHIV, different 
authors used scores of either 26 or 27, based on their local 
validation studies. Chan et al. used MoCA in a study where 
a diagnosis of HAND was made in 22.7% of 132 HIV-positive 
patients in Singapore. In the study, Chan stated that local 
validation studies had a cut-off score of 26 or 27 out of 30, 
even though the studies were still under peer review.17 In a 
study carried out on 100 HIV-positive patients to screen for 
neurocognitive impairment with the use of MoCA as a 
screening tool, it was found to have a sensitivity of 85%, 
specificity of 40%, negative predictive value of 48% and a 
positive predictive value of 81%, with a cut-off score of < 26.19 
Raising the cut-off point of the MoCA was shown to increase 
sensitivity but reduce specificity.3,20 Making a diagnosis of 
HAND according to Frascati criteria,7 which was adopted by 
the AAN in 2007, requires the use of a neuropsychological 
battery of tests, as well as comparison with normative data 
from the population. The MoCA tool attempts to assess the 
eight domains of cognition to help in screening of patients 
who would then be referred to neuropsychologists for 
definitive diagnosis. These domains include visuospatial or 
executive functioning, naming, attention, concentration 
and calculation, language, abstraction, delayed recall and 
orientation. In this study, the MoCA was utilised for 
screening for cognitive impairment, with a cut-off score less 
than 26 defined as cognitive impairment.
The Lawton Instrumental Activities of Daily Living (IADL) 
assesses the eight domains of functions and is most useful for 
identifying how a person is functioning at the present time 
(Appendix 3). These domains include the ability to use a 
telephone, shop, do housekeeping, complete laundry work, 
transport, and the responsibility for taking medication and to 
handle finances. The validity was tested by determining its 
correlations with four scales that measured assessment of 
functional status and all correlations were found to be 
significant at 0.01 or 0.05 level.21 The tool was also used by 
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Chan17 in evaluation of HAND in the population of 132 
HIV-positive patients. High scores depict independence, 
while low scores depict high levels of dependence.
The World Health Organization (WHO) recommends ART 
adherence of > 95% to achieve the best treatment outcomes.5,6
Justification
The HIV prevalence in Kenya is 5.6% according to the Kenya 
AIDS Indicator Survey of 2012 (KAIS 2012) report released in 
2014.22 About 84.5% of HIV-positive patients who are eligible 
for ART were on treatment according to the 2012 survey. The 
adherence rates are still suboptimal as shown by a study 
carried out at Aga Khan University Hospital in 2011, which 
showed that only 52% of the population had adherence rates 
above 95% despite 82% of the patients self-reporting an 
adherence rate of more than 95%.4
Although there has been a decline in the incidence of HAD in 
the ART era, the prevalence rate of HAND remains elevated.23 
Cognitive assessment is not routinely assessed in our HIV 
clinics and is also not recommended in current Kenyan 
treatment guidelines.
Poor judgement, memory impairment and poor decision-
making as components of cognition may lead to poor 
adherence rates in HIV-positive patients who are on ART.24,25 
One primary cause of treatment failure has been linked to 
HIV resistance, related to suboptimal adherence rates to 
ART.2 Cognitive impairment may lead to failure to maintain 
a stable income-generating activity as well as poor decision-
making in lifestyle choices, such as taking medication.3
Patients, who are HIV-positive with other comorbid 
conditions, will be required to take several medications, and 
compliance to these medications requires good cognition.
In patients with drug resistance requiring complex regimens 
or those taking concurrent treatment for tuberculosis or 
Pneumocystis jirovecii pneumonia, poor cognition may lead to 
further treatment failure.
Early recognition of neurocognitive impairment will also 
guide clinicians towards appropriate referrals and further 
tests for patients as well as strengthening of adherence 
counselling.
Knowledge of how neurocognitive impairment affects ART 
adherence will therefore significantly contribute to guidelines 
in dealing with this potential factor in improving outcomes 
for PLWHIV.
Primary objective
To determine the association between the milder forms of 
cognitive impairment (ANI and MND) and adherence to 
ART in PLWHIV attending clinic at Aga Khan University 
Hospital, Nairobi.
Methodology
Study design
The study is an analytical cross-sectional survey assessing 
the association between mild cognitive impairment 
(asymptomatic and MND) and adherence to treatment with 
ART in HIV-positive patients.
Study setting and period
The study was carried out in the HIV clinic at Aga Khan 
University Hospital (AKUHN), situated in Nairobi, Kenya.
About 635 HIV-positive patients are on follow-up at the 
AKUHN’s infectious diseases clinics, out of which an 
estimated 95% (603) are on treatment with ART (about 
500 [83%] of them for at least six months, hence eligible for 
this study). The study was conducted between October 2015 
and May 2016, a period during which all those eligible for the 
study visited the clinic at least once and had a chance to be 
selected to participate.
Sample size calculation
The sample size for this study was derived using a sampling 
formula for a finite population, with an error margin no 
larger than 0.05.26 This is as shown below:
=
+
−1  1
n m
m
N
 [Eqn 1]
where
( )
=
−α  1/2
2
2m
Z p p
d
 [Eqn 2]
So that:
•	 Z
α/2 = standard normal variate (1.96) for level of 
significance (0.05);
•	 N = total number of population, which is 500;
•	 n = sample size;
•	 m = sample size necessary for estimating the prevalence 
of the total population, N;
•	 d = error, 0.05;
•	 p = prevalence of non-adherence in HIV-positive patients 
attending clinic, estimated at 48% from a previous study 
conducted in the same population4;
•	
( )
=
−1.96 *0.48 1  0.48
0.05
2 
2m  (m = 383.54);
•	 Therefore, =
+
−
383.54
1  383.54 1
500
n  (n = 218 patients).
Inclusion criteria
•	 ≥	18 years of age and ≤	65 years;
•	 HIV-positive on ART for over six months;
•	 Ability to read and write in English.
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Exclusion criteria
•	 Patients with an opportunistic infection affecting the CNS 
in the last 12 months or non-CNS infection in the last 
three months, or known to have a mental illness such as 
depression or schizophrenia or having epilepsy.
•	 History of current substance abuse.
•	 History of head injury with loss of consciousness 
exceeding 30 min.
Sampling technique and data collection
Over the study period, a total of 635 patients attended the 
clinics, of whom, 500 were eligible for the study.
Consecutive sampling was utilised, recruiting every eligible 
clinic patient into the study as they visited the clinic during 
this period, until the sample size was met.
The following is the recruitment procedure:
•	 HIV-positive patients were recruited from the HIV clinic 
at AKUHN by the principal investigator during opening 
hours (Monday to Saturday).
•	 Informed consent was obtained from the patients who 
had met the eligibility criteria. The principal investigator 
discussed the consent process with the patients in detail 
and they were given a chance to decline participation.
•	 The patients were provided with a questionnaire to obtain 
biographical data.
•	 The MoCA questionnaire was administered to patients 
to assess for cognitive function, with a cut-off less 
than 26.
•	 The patient’s functional status at work and at home was 
assessed using the Lawton’s IADL tool, by self-reporting.
•	 Self-reported adherence to ART using the simplified 
medication adherence questionnaire (SMAQ) tool was 
also established.
•	 Medication possession ratio (MPR) was then calculated 
based on the pharmacy dispensing records for about three – 
eight months to assess their possession rate as an objective 
measure of adherence using the following formula:
×
Pills dispensed/pills prescribed per day
Number of days between refills
100%.  [Eqn 3]
The MPR is a validated, pharmacy-based method for 
assessment of adherence in areas where pill count is not 
normally done as is the case at the Aga Khan University 
Hospital, Nairobi.27
For a diagnosis of HAND to be made, the Frascati criteria, 
adopted by AAN, need to be met; however, for screening 
purposes, normal cognition is any score of 26 and above. 
The MoCA cannot distinguish between HAD and minor 
forms of neurocognitive impairment. However, as per the 
Frascati criteria, low cognitive scores, together with 
increased dependence on others for IADL, would give a 
diagnosis of HAD.7
Optimal adherence was defined as 95% and above, as per the 
WHO’s recommendations, with suboptimal adherence being 
any value less than 95%.5,6 The MPR was calculated for each 
patient based on the pharmacy dispensing records, for at 
least three months.
The SMAQ was utilised for assessment of self-reported 
adherence for comparison with the MPR, and it has been 
validated for use in the HIV-positive population, with a 
sensitivity of 72% and a specificity of 91%.28,29
Data analysis
This study utilised a quantitative design involving collection 
and analysis of quantitative primary data about pre-defined 
variables. Additional data were also collected on other 
patient-specific attributes that are likely to affect adherence 
patterns.
Descriptive statistics were used to summarise the data 
including frequency tables for demographic characteristics of 
the participants. Other baseline characteristics related to the 
participants’ HIV treatment were also analysed.
The patients were then grouped based on their neurocognitive 
status (with and without impairment).
Other baseline factors with potential to affect adherence in 
the two patient groups were also compared. Thereafter, 
bivariate analysis using chi-square test was used to test the 
relationship between individual predictor and outcome 
variables. The choice of chi-square test in this regard is 
especially suited to conducting hypothesis tests for 
categorical data such as that used for this study.
Data collected, collated and cleaned in Excel worksheets 
were eventually analysed using Statistical Package for Social 
Sciences (SPSS) version 21.
Ethical consideration
The study was carried out with approval from the Department 
of Internal Medicine, AKUHN and the Ethical and Scientific 
Review Committee. Informed written consent was obtained 
from all participants.
Results
A total of 500 patients were found to be eligible for the study. 
A final sample size of 218 patients was recruited to participate 
in the study. For those not eligible, the main reasons for 
ineligibility were duration on ART of less than six months, 
presence of space occupying lesions and other central 
nervous system abnormalities, and extremes of age above 
65 years. No patients were found to have HAD, 69% 
had minor neurocognitive dysfunction and 31% had no 
neurocognitive dysfunction. Those selected underwent 
adherence assessment. The overall optimal adherence rate 
for this population was 66% by objective assessment (MPR) 
and 77% by subjective assessment (SMAQ).
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Summary of baseline characteristics
Of the 218 participants selected for the study, a total of 
215 completed the MoCA neurocognitive assessment. 
The study population varied according to different baseline 
demographic and HIV treatment-related characteristics 
(Tables 1 and 2).
Those with normal neurocognitive function had a mean age 
of 42.3 years, while the mean age for those with impaired 
cognitive function was 45.5 years.
The source of a patient’s medicine was thought to be 
important, as it determined the availability of the medicine 
and therefore adherence to treatment plans. This factor also 
determined how many patients could be assessed objectively 
by MPR owing to availability of pharmacy records. Similarly, 
income and therefore ability to afford medication was 
important, as it related to adherence to treatment and 
outcomes thereafter.
Bivariate analysis: Cognitive impairment and adherence 
to antiretroviral therapy (as measured by medication 
possession ratio)
A bivariate analysis was conducted to determine the existence 
of any significant association between the presence of mild 
cognitive impairment as measured by the MoCA score and 
the ability to adhere to prescribed treatment with ART as 
measured objectively through calculation of the MPR. The 
results showed a lack of significant association (p = 0.490) 
between the two variables (Table 3).
Bivariate analysis: Cognitive impairment and adherence 
to antiretroviral therapy (as measured by simplified 
medical adherence questionnaire)
A bivariate analysis was conducted to determine the existence 
of any significant association between the presence of mild 
cognitive impairment as measured by the MoCA score and 
the ability to adhere to prescribed treatment with ART as 
measured subjectively through the SMAQ questionnaire. The 
results showed a lack of significant association (p = 0.658) 
between the two variables (Table 4).
Secondary analysis
Secondary analysis was conducted for any association 
between baseline patient characteristics and the observed 
adherence patterns; as such, characteristics could serve as 
confounders to the outcome variable. Table 5 shows the 
outcomes of the bivariate analysis between selected 
baseline characteristics of participants and the adherence 
patterns as assessed objectively by MPR and subjectively 
by SMAQ.
The numbers do not consistently add up owing to some 
missing data. An example is MPR calculation owing to 
patients collecting their medication from outside the 
hospital.
TABLE 2: Human immunodeficiency virus treatment-related characteristics.
Characteristic Variable MoCA score
Normal Normal  
(%)
Impaired Impaired 
(%)
Duration since HIV 
diagnosis (years)
Mean 7.6 years - 8.0 years -
Duration on ART 
(years)
Mean 5.47 years - 6.69 years -
Source of ART 
medicines
AKUHN 57 85 128 88
Other 10 15 18 12
Payment for 
medication
Cash 18 27 41 28
Insurance 43 64 95 65
Insurance/cash 1 1 5 3
Free 5 7 5 3
ART regimen EFV-based 48 72 98 70
PI-based 11 16 32 23
Other 8 12 10 7
First viral load Suppressed 51 88 103 82
Not suppressed 7 12 22 18
Latest viral load Suppressed 41 68 84 67
Not suppressed 19 32 42 33
AKUHN, Aga Khan University Hospital, Nairobi; ART, antiretroviral therapy; HIV, human 
immunodeficiency virus; MoCA, Montreal Cognitive Assessment; EFV, Efavirenz; PI, Protease 
Inhibitor.
TABLE 1: Baseline demographic characteristics.
Baseline 
characteristic
Variable MoCA neurocognitive assessment score
Normal % Impaired %
Overall outcome - 67 31 147 69
Age Mean 42.3 years - 45.5 years -
Gender Male 34 51 67 46
Female 33 49 80 54
Education level Primary 1 2 11 8
Secondary 9 13 29 20
Tertiary 57 85 106 73
Marital status Married 37 55 101 69
Widowed 11 16 14 10
Divorced or 
separated
4 6 10 7
Single 15 22 21 14
Living with family Yes 57 85 127 86
No 10 15 20 14
Employment status Employed 48 72 96 66
Self-employed 15 22 40 27
Unemployed 4 6 10 7
Level of income (US 
dollars per month) 
0–100 5 8 22 15
110–500 12 19 46 32
510–1000 20 32 31 22
> 1000 26 41 45 32
MoCA, Montreal Cognitive Assessment.
TABLE 3: Bivariate analysis of Montreal Cognitive Assessment scores and 
Medication Possession Ratio.
Neurocognitive 
assessment
Variable Adherence by MPR p
Optimal (number 
of participants)
Suboptimal (number 
of participants)
MoCA neurocognitive 
assessment score
Normal 34 15 0.490
Impaired 74 42
MPR, medication possession ratio; MoCA, Montreal Cognitive Assessment.
TABLE 4: Bivariate analysis of Montreal Cognitive Assessment and simplified 
medication adherence questionnaire.
Neurocognitive 
assessment
Variable Adherence by SMAQ p
Adherent  
(no. of participants)
Non-adherent  
(no. of participants)
MoCA 
neurocognitive 
assessment score
Normal 50 17 0.658
Impaired 113 33
MoCA, Montreal Cognitive Assessment; SMAQ, simplified medication adherence questionnaire.
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As shown in Table 5, there was no statistically significant 
association between any baseline patient characteristics and 
adherence by either MPR or SMAQ (all p-values were > 0.05).
A sub-analysis was conducted to determine the association 
between the measures of cognitive impairment using MoCA 
and the latest viral load as a surrogate measure of adherence. 
With a cut-off of 1000 copies per millilitre (mL), patients with 
a viral load greater than 1000 copies/mL were considered not 
suppressed and therefore non-adherent to ART, while 
patients with a viral load less than 1000 copies/mL were 
considered to have a suppressed viral load and therefore 
adherent to ART.30 There was no significant association 
between the presence of cognitive impairment and the 
treatment outcomes as measured by viral load (p = 0.238) 
(Table 6).
Discussion of findings
The study was carried out among patients attending the 
clinic who are on follow-up, and as far as activities of daily 
living assessment were concerned, they were independent. 
The population studied had a mean age of 46.5 years in males 
and 42.7 years in females. This is an older age group as 
compared with the national statistics according to KAIS, 
2012, which shows that HIV prevalence is the highest among 
women aged 30–39 years.22 However, among the males, it is 
in line with the national statistics which show the highest 
prevalence between 45 and 49 years of age.
The rate of cognitive impairment in this group is high, which 
corresponds to some of the studies carried out, such as the 
CHARTER study, which showed a 52% prevalence of 
HANDs, with majority being asymptomatic and mild 
cognitive disorders, and only 2% of this population having 
HAD. On exclusion of patients with severe confounding 
comorbidities, 46.9% of the remaining patients received a 
diagnosis of HAND, and 70% of this population had ANI.12 
In the current study, there was no patient presumably 
identified to have HAD, as assessed by both MoCA and 
Lawton score. One patient reported that she was independent 
in IADL, even though she had a low MoCA score of 9/30.
The high prevalence of cognitive impairment in this group 
could be because of several factors such as the MoCA, though 
validated in other countries, being not wholly culturally 
appropriate in our circumstances. Most participants had 
difficulty recalling some unfamiliar items such as daisy, 
velvet and the word couch, as part of the statement in the 
language section, which were words that needed to be 
assessed as part of cognitive assessment. This was also seen 
in a study by Robbins et al., which was carried out in South 
Africa among Xhosa-speaking people. They had to translate 
the MoCA to the Xhosa language as well as modify it for the 
tool to be culturally acceptable.3
The MoCA screening tool was initially designed to screen for 
mild cognitive impairment by Nasreddine et al. and the cut-
off score was set at less than 26.18 However, several validation 
studies in the HIV setting have used different cut-off scores. 
This could account for the classification of patients as having 
normal versus impaired cognition, based on the cut-off score 
set. In settings where a complete neurophysiological battery 
TABLE 6: Bivariate analysis with use of the latest viral load as a measure of 
adherence.
MoCA score 
assessment
Latest viral load p
Viral load suppressed 
(< 1000 copies/mL)
Viral load not suppressed 
(> 1000 copies/mL)
Normal 57 3 0.238
Impaired 115 13
Unknown 30 -
MoCA, Montreal Cognitive Assessment.
TABLE 5: Bivariate analysis for baseline characteristics and adherence.
Variable Category Adherence by MPR (no. of participants) Adherence by SMAQ (no. of participants)
Optimal Suboptimal p Adherent Non-adherent p
Sex Male 55 28 0.870 78 22 0.633
Female 54 29 85 28
Education level Primary 8 2 0.443 9 3 0.918
Secondary 24 10 30 8
Tertiary 77 45 123 39
Marital status Married 72 39 0.857 112 26 0.077
Widowed 10 7 19 6
Divorced or separated 8 3 8 6
Single 18 8 23 12
Living with family Yes 91 51 0.298 143 41 0.301
No 18 6 20 9
Employment status Employed 75 33 0.348 115 28 0.079
Self-Employed 27 20 39 16
Unemployed 7 4 8 6
Payment mode Cash 30 19 0.195 46 13 0.879
Insurance 75 35 106 31
Free 2 0 7 3
Insurance or cash 1 3 4 2
Source of medicines AKUHN 104 55 0.949 141 43 0.850
Other 4 2 21 7
MPR, medication possession ratio; SMAQ, simplified medication adherence questionnaire.
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of tests cannot be done readily, MoCA is a good screening 
tool with high enough sensitivity in milder forms of cognitive 
impairment.
The respondents were recruited during clinic hours in the 
morning. Most of the patients were employed and as they 
were coming in the routine clinic time, they were either 
coming from work – night duty, or on their way to work. The 
sense of spending more time than their usual clinic hours 
seemed to be a factor in some of their performances, as some 
patients reported that they were going to be late, were tired 
and could therefore not concentrate well or were not in the 
best state of mind to respond to the questions. It is postulated 
that this could be one of the factors contributing to the 
high prevalence rate of cognitive impairment. Cognitive 
assessment is ideally a continuous process. The MoCA tool is 
designed for screening for cognitive impairment, but 
definitive diagnosis is done by a neurophysiologic battery of 
tests, such as the HNRC battery of tests. It would be necessary 
to carry out the tests several times and get an average score; 
however, as this was a cross-sectional survey, we only relied 
on one meeting with the patient to make our assessment. The 
study design also limited the extent to which causality could 
be established. The study was also limited by lack of data for 
patients who obtained their medication or did their laboratory 
tests outside the hospital.
According to this study, the adherence rate, calculated by 
MPR, was 66%, compared with 77% as per subjective testing. 
These results are comparable to a study conducted in 
AKUHN, Kenya.4
Our study had several strengths. This is the first study, to our 
knowledge, that has been carried out in Kenya, using MoCA 
as a screening tool for cognitive impairment and associating 
it with adherence to ART. It therefore gives a prevalence of 
asymptomatic and mild cognitive impairment in this 
population, whereas previous studies assessed prevalence of 
HAND in general, and did not focus on the mild forms of 
cognitive impairment. The earlier studies also used IHDS 
and MMSE, which have been found to be less sensitive for 
subcortical dysfunction that is more dominant in the mild 
forms of HAND.
The sample size of 218, for a finite population of 500 eligible 
patients, was adequate for assessment of the association 
between milder forms of cognitive impairment and adherence 
to ART; hence, the results may be generalisable in similar 
settings but should be extrapolated to other populations with 
caution because of the specific characteristics of the 
population studied.
Acknowledgements
The author, Violet Awori, would like to acknowledge the 
support received from her supervisors Prof. Yonga, Dr Reena 
and Dr Mativo; the nurses at the Communicable Diseases 
Clinic; Dr. Hawken and Dr Magada; study participants; and 
her family during the study period.
Competing interests
The authors declare that there were no conflicts of interest 
during the writing of this article.
Authors’ contributions
V.A. was the main author. R.S. and P.M. were the content 
supervisors, while G.Y. was the methodology supervisor.
References
 1. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B. Screening for cognitive 
impairment in human immunodeficiency virus. Clin Infect Dis. 2011;53(8):836–842. 
https://doi.org/10.1093/cid/cir524
 2. Valcour VG. Evaluating cognitive impairment in the clinical setting: Practical 
screening and assessment tools. Top Antivir Med. 2011;19(5):175–180.
 3. Robbins RN, Joska JA, Thomas KGF, et al. Exploring the utility of the Montreal 
Cognitive Assessment to detect HIV-associated neurocognitive disorder: The 
challenge and need for culturally valid screening tests in South Africa. Clin 
Neuropsychol. 2013;27:437–454. https://doi.org/10.1080/13854046.2012.759627
 4. Mbugua E. The influence of depression on adherence among HIV positive 
patients. Unpublished data. Nairobi, Kenya: Aga Khan University; 2011.
 5. Hardon A, Davey S, Gerrits T, et al. From access to adherence: The challenges of 
antiretroviral treatment. Studies from Botswana, Tanzania and Uganda. From 
Access to Adherence Challenges Antiretrovir Treat Stud from Botswana, Tanzania 
Uganda. 2006;301:1–320.
 6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy 
and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30. 
https://doi.org/10.7326/0003-4819-133-1-200007040-00004
 7. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-
associated neurocognitive disorders. Neurology. 2007;69:1789–1799. https://doi.
org/10.1212/01.WNL.0000287431.88658.8b
 8. Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive 
impairment in the cART era: A review. AIDS (London, England). 2011;25:561–575. 
https://doi.org/10.1097/QAD.0b013e3283437f9a
 9. Lawler K, Mosepele M, Ratcliffe S, et al. Neurocognitive impairment among HIV-
positive individuals in Botswana: A pilot study. J Int AIDS Soc. 2010;13:1–9. 
https://doi.org/10.1186/1758-2652-13-15
10. Zaheer B. Cognitive dysfunction among HIV ositive patients attending CCC at 
Kenyatta National Hospital. Unpublished. 2011
11. Habib AG, Yakasai AM, Owolabi LF, et al. Neurocognitive impairment in HIV-1-
infected adults in Sub-Saharan Africa: A systematic review and meta-analysis. Int 
J Infect Dis. 2013;17(10):e820–e831. https://doi.org/10.1016/j.ijid.2013.06.011
12. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders 
persist in the era of potent antiretroviral therapy: Charter Study. Neurology. 
2010;75:2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727
13. Robbins RN, Remien RH, Mellins CA, Joska JA, Stein DJ. Screening for HIV-
associated dementia in South Africa: Potentials and pitfalls of task-shifting. AIDS 
Patient Care STDS. 2011;25(10):587–593. https://doi.org/10.1089/apc.2011.0154
14. Joska JA, Westgarth-Taylor J, Hoare J, et al. Validity of the International HIV 
Dementia Scale in South Africa. AIDS Patient Care STDS. 2011;25(2):95–101. 
https://doi.org/10.1089/apc.2010.0292
15. Joska JA, Westgarth-Taylor J, Myer L, et al. Characterization of HIV-associated 
neurocognitive disorders among individuals starting antiretroviral therapy in 
South Africa. AIDS Behav. 2011;15:1197–1203. https://doi.org/10.1007/s10461-
010-9744-6
16. Robbins, RN, Joska J. Exploring the utility of the Montreal Cognitive Assessment to 
detect HIV associated neurocognitive disorder:The challenge and need for culturally 
valid screening tests in South Africa. Clin Neuropsychol. 2012;29(3):997–1003.
17. Chan LG, Kandiah N, Chua A. HIV-associated neurocognitive disorders (HAND) in a 
South Asian population – Contextual application of the 2007 criteria. BMJ Open. 
2012;2:e000662–e000662. https://doi.org/10.1136/bmjopen-2011-000662
18. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, 
MoCA: A brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 
2005;53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
19. Hasbun R, Eraso J, Ramireddy S, et al. Utility of the Montreal Cognitive Assessment 
Test. J AIDS Clin Res. 2013;3(10):186.
20. Overton ET, Azad TD, Parker N, et al. The Alzheimer’s disease-8 and Montreal 
Cognitive Assessment as screening tools for neurocognitive impairment in HIV-
infected persons. J Neurovirol. 2013;19:109–116. https://doi.org/10.1007/s13365- 
012-0147-5
21. Lawton MP, Brody EM. Assessment of older people: Self-maintaining and 
instrumental activities of daily living. Gerontologist. 1969;9:179–186. https://doi.
org/10.1093/geront/9.3_Part_1.179
22. National AIDS and STI Control Programme (NASCOP). Kenya AIDS Indicator Survey 
2012:Final Report. Nairobi: NASCOP; 2014.
23. Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive 
impairment in early diagnosed and managed HIV-infected persons. Neurology. 
2013;80:371–379. https://doi.org/10.1212/WNL.0b013e31827f0776
Page 8 of 10 Original Research
http://www.sajhivmed.org.za Open Access
24. Andrade ASA, Deutsch R, A Celano S, et al. Relationships among neurocognitive 
status, medication adherence measured by pharmacy refill records, and virologic 
suppression in HIV-infected persons. J Acquir Immune Defic Syndr [serial online]. 
2013 [n.d.];62(3):282–292. Available from: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid=3906725&tool=pmcentrez&rendertype=abstract
25. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ 
adults: Effects of cognitive dysfunction and regimen complexity. Neurology. 
2002;59(12):1944–1950. https://doi.org/10.1212/01.WNL.0000038347.48137.67
26. Israel GD. Determining sample size. Agric Educ Commun Ser [serial online]. 2013 
[n.d.];1–5. Available from: http://edis.ifas.ufl.edu
27. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess 
adherence to antiretroviral therapy: Review of the literature and implications for 
treatment monitoring. Clin Infect Dis. 2011;52:493–506. https://doi.org/10.1093/
cid/ciq167
28. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication 
adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA 
Study. AIDS. 2002;16:605–613.
29. Elias L, Pérez Elías MJ, Rodriguez Sagrado MA, et al. Antiretroviral (ART) adherence 
(adh) evaluation in large populations: Is it necessary to assess adherence using 
more than one method? Poster exhibition: Sydney – IAS 2007: Abstract no. 
WEPEB109.
30. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization’s 
global strategy for prevention and assessment of HIV drug resistance. Antiviral 
Ther. 2008;13:1–13.
Page 9 of 10 Original Research
http://www.sajhivmed.org.za Open Access
Appendix 1
FIGURE 1-A1: Montreal Cognitive Assessment (MoCA).
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Appendix 2
Appendix 3
Lawton’s instrumental activities of daily living
Please check the box that most applies for each activity:
FIGURE 1-A2: Simplified Medication Adherence Questionnaire (SMAQ)
Monitoring/esmang adherence to art in general
(Knobel et al. 2002)
SCORING: A positive response to any of the qualitative questions, more
than two doses missed over the past week, or over two days of total
non-medication during the past three months = non-adherent
(Knobel et al. 2002).
6. Over the past 3 months, how many days have you not
     taken any medicine at all?
≤ 2 days > 2 days
4. Thinking about the last week. How oen have you not taken your
    medicine?
Never
1 ± 2 mes
3 ± 5 mes
6 ± 10 mes
> 10 mes
1. Do you ever forget to take your medicine? Yes No
2. Are you careless at mes about taking your medicine? Yes No
3. Somemes if you feel worse, do you stop taking your
    medicines?
Yes No
5. Did you not take any of your medicine over the
     past weekend?
Yes No
Activity Need no help  
(2 pts. each)
Need some help  
(1 pt. each)
Unable to do at all  
(0 pts. each)
1. Using the 
telephone
___ ___ ___
2. Getting to places 
beyond walking 
distance
___ ___ ___
3. Grocery shopping ___ ___ ___
4. Preparing meals ___ ___ ___
5. Doing housework 
or handyman work
___ ___ ___
6. Doing laundry ___ ___ ___
7. Taking 
medications
___ ___ ___
8. Managing money ___ ___ ___
Total Score: ___ = (___ x 2 =) ___ + (___ x 1=) ___ + 0
Source: Lawton and Brody.21 Copyright (c) by The Gerontological Society of America. Used by 
permission of the Publisher.
Date: Name
